<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241011121246&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;ff=20241011121246&amp;utm_medium=rss&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 11 Oct 2024 16:12:48 +0000</lastbuilddate>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ANGPTL3/8 potently inhibited GPIHBP1-LPL enzymatic activity, consistent with its positive association with serum lipids. However, ANGPTL3/8, LDL-C, and triglyceride levels were not associated with cardiovascular death in the LURIC and getABI cohorts. In contrast, concentrations of ANGPTL4/8 and particularly CD-ANGPTL4 were positively associated with inflammation, the prevalence of diabetes, and cardiovascular mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069272. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ANGPTL3/4/8 (angiopoietin-like proteins 3, 4, and 8) are important regulators of LPL (lipoprotein lipase). ANGPTL8 forms complexes with ANGPTL3 and ANGPTL4. ANGPTL4/8 complex formation converts ANGPTL4 from a furin substrate to a plasmin substrate, and both cleavages generate similar C-terminal domain-containing (CD)-ANGPTL4 fragments. Whereas several studies have investigated associations of free ANGPTL proteins with cardiovascular risk, there are no data describing associations of the complexes and CD-ANGPTL4 with outcomes or describing the effects of the complexes on LPL bound to GPIHBP1 (glycosylphosphatidylinositol HDL-binding protein 1).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Recombinant protein assays were used to study ANGPTL protein and complex effects on GPIHBP1-LPL activity. ANGPTL3/8, ANGPTL3, ANGPTL4/8, and CD-ANGPTL4 were measured with dedicated immunoassays in 2394 LURIC (Ludwigshafen Risk and Cardiovascular Health) study participants undergoing coronary angiography and 6188 getABI study (German Epidemiological Trial on Ankle Brachial Index) participants undergoing ankle brachial index measurement. There was a follow-up for cardiovascular death with a median (interquartile range) duration of 9.80 (8.75-10.40) years in the LURIC study and 7.06 (7.00-7.14) years in the getABI study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: ANGPTL3/8 potently inhibited GPIHBP1-LPL activity and showed positive associations with LDL-C (low-density lipoprotein cholesterol) and triglycerides (both <i>P</i>&lt;0.001). However, in neither study did ANGPTL3/8 correlate with cardiovascular death. Free ANGPTL3 was positively associated with cardiovascular death in the getABI study but not the LURIC study. ANGPTL4/8 and especially CD-ANGPTL4 were positively associated with the prevalence of diabetes, CRP (C-reactive protein; all <i>P</i>&lt;0.001), and cardiovascular death in both studies. In the LURIC and getABI studies, respective hazard ratios for cardiovascular mortality comparing the third with the first ANGPTL4/8 tertile were 1.47 (1.15-1.88) and 1.68 (1.25-2.27) when adjusted for sex, age, body mass index, and diabetes. For CD-ANGPTL4, these hazard ratios were 2.44 (1.86-3.20) and 2.76 (2.00-3.82).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ANGPTL3/8 potently inhibited GPIHBP1-LPL enzymatic activity, consistent with its positive association with serum lipids. However, ANGPTL3/8, LDL-C, and triglyceride levels were not associated with cardiovascular death in the LURIC and getABI cohorts. In contrast, concentrations of ANGPTL4/8 and particularly CD-ANGPTL4 were positively associated with inflammation, the prevalence of diabetes, and cardiovascular mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39392008</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069272>10.1161/CIRCULATIONAHA.124.069272</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392008</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Günther Silbernagel</dc:creator>
<dc:creator>Yan Q Chen</dc:creator>
<dc:creator>Hongxia Li</dc:creator>
<dc:creator>Deven Lemen</dc:creator>
<dc:creator>Yi Wen</dc:creator>
<dc:creator>Eugene Y Zhen</dc:creator>
<dc:creator>Martin Rief</dc:creator>
<dc:creator>Marcus E Kleber</dc:creator>
<dc:creator>Graciela Delgado</dc:creator>
<dc:creator>Mark A Sarzynski</dc:creator>
<dc:creator>Yue-Wei Qian</dc:creator>
<dc:creator>Boerge Schmidt</dc:creator>
<dc:creator>Raimund Erbel</dc:creator>
<dc:creator>Ulrike Trampisch</dc:creator>
<dc:creator>Angela P Moissl</dc:creator>
<dc:creator>Henrik Rudolf</dc:creator>
<dc:creator>Heribert Schunkert</dc:creator>
<dc:creator>Andreas Stang</dc:creator>
<dc:creator>Winfried März</dc:creator>
<dc:creator>Hans J Trampisch</dc:creator>
<dc:creator>Hubert Scharnagl</dc:creator>
<dc:creator>Robert J Konrad</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality</dc:title>
<dc:identifier>pmid:39392008</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069272</dc:identifier>
</item>
<item>
<title>YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39392007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our data reveal that YAP5SA overcomes the mechanically constrained myocardial microenvironment to induce mitotic rounding with cardiomyocyte division, thus providing new insights into the in vivo mechanisms that maintain cell cycle quiescence in adult mammals.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.123.066004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Many specialized cells in adult organs acquire a state of cell cycle arrest and quiescence through unknown mechanisms. Our limited understanding of mammalian cell cycle arrest is derived primarily from cell culture models. Adult mammalian cardiomyocytes, a classic example of cell cycle arrested cells, exit the cell cycle postnatally and remain in an arrested state for the life of the organism. Cardiomyocytes can be induced to re-enter the cell cycle by YAP5SA, an active form of the Hippo signaling pathway effector YAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed clonal analyses to determine the cell kinetics of YAP5SA cardiomyocytes. We also performed single-cell RNA sequencing, marker gene analysis, and functional studies to examine how YAP5SA cardiomyocytes progress through the cell cycle.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We discovered that YAP5SA-expressing cardiomyocytes divided efficiently, with >;20% of YAP5SA cardiomyocyte clones containing ≥2 cardiomyocytes. YAP5SA cardiomyocytes re-entered cell cycle at the G1/S transition and had an S phase lasting ≈48 hours. Sarcomere disassembly is required for cardiomyocyte progression from S to G2 phase and the induction of mitotic rounding. Although oscillatory Cdk expression was induced in YAP5SA cardiomyocytes, these cells inefficiently progressed through G2 phase. This is improved by inhibiting P21 function, implicating checkpoint activity as an additional barrier to YAP5SA-induced cardiomyocyte division.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our data reveal that YAP5SA overcomes the mechanically constrained myocardial microenvironment to induce mitotic rounding with cardiomyocyte division, thus providing new insights into the in vivo mechanisms that maintain cell cycle quiescence in adult mammals.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39392007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39392007</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066004>10.1161/CIRCULATIONAHA.123.066004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39392007</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Yuka Morikawa</dc:creator>
<dc:creator>Jong H Kim</dc:creator>
<dc:creator>Rich Gang Li</dc:creator>
<dc:creator>Lin Liu</dc:creator>
<dc:creator>Shijie Liu</dc:creator>
<dc:creator>Vaibhav Deshmukh</dc:creator>
<dc:creator>Matthew C Hill</dc:creator>
<dc:creator>James F Martin</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>YAP Overcomes Mechanical Barriers to Induce Mitotic Rounding and Adult Cardiomyocyte Division</dc:title>
<dc:identifier>pmid:39392007</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066004</dc:identifier>
</item>
<item>
<title>A Rare Noncoding Enhancer Variant in &lt;em>;SCN5A&lt;/em>; Contributes to the High Prevalence of Brugada Syndrome in Thailand</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39391988/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the SCN5A locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069041. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Brugada syndrome (BrS) is a cardiac arrhythmia disorder that causes sudden death in young adults. Rare genetic variants in the <i>SCN5A</i> gene encoding the Na<sub>v</sub>1.5 sodium channel and common noncoding variants at this locus are robustly associated with the condition. BrS is particularly prevalent in Southeast Asia but the underlying ancestry-specific factors remain largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Genome sequencing of BrS probands and population-matched controls from Thailand was performed to identify rare noncoding variants at the <i>SCN5A-SCN10A</i> locus that were enriched in patients with BrS. A likely causal variant was prioritized by computational methods and introduced into human induced pluripotent stem cell (hiPSC) lines using CRISPR-Cas9. The effect of the variant on <i>SCN5A</i> expression and Na<sub>v</sub>1.5 sodium channel current was then assessed in hiPSC-derived cardiomyocytes (hiPSC-CMs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A rare noncoding variant in an <i>SCN5A</i> intronic enhancer region was highly enriched in patients with BrS (detected in 3.9% of cases with a case-control odds ratio of 45.2). The variant affects a nucleotide conserved across all mammalian species and predicted to disrupt a Mef2 transcription factor binding site. Heterozygous introduction of the enhancer variant in hiPSC-CMs caused significantly reduced <i>SCN5A</i> expression from the variant-containing allele and a 30% reduction in Na<sub>v</sub>1.5-mediated sodium current density compared with isogenic controls, confirming its pathogenicity. Patients with the variant had severe phenotypes, with 89% experiencing cardiac arrest.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This is the first example of a functionally validated rare noncoding variant at the <i>SCN5A</i> locus and highlights how genome sequencing in understudied populations can identify novel disease mechanisms. The variant partly explains the increased prevalence of BrS in this region and enables the identification of at-risk variant carriers to reduce the burden of sudden cardiac death in Thailand.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39391988/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39391988</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069041>10.1161/CIRCULATIONAHA.124.069041</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39391988</guid>
<pubDate>Fri, 11 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Roddy Walsh</dc:creator>
<dc:creator>John Mauleekoonphairoj</dc:creator>
<dc:creator>Isabella Mengarelli</dc:creator>
<dc:creator>Fernanda M Bosada</dc:creator>
<dc:creator>Arie O Verkerk</dc:creator>
<dc:creator>Karel van Duijvenboden</dc:creator>
<dc:creator>Yong Poovorawan</dc:creator>
<dc:creator>Wanwarang Wongcharoen</dc:creator>
<dc:creator>Boosamas Sutjaporn</dc:creator>
<dc:creator>Pharawee Wandee</dc:creator>
<dc:creator>Nitinan Chimparlee</dc:creator>
<dc:creator>Ronpichai Chokesuwattanaskul</dc:creator>
<dc:creator>Kornkiat Vongpaisarnsin</dc:creator>
<dc:creator>Piyawan Dangkao</dc:creator>
<dc:creator>Cheng-I Wu</dc:creator>
<dc:creator>Rafik Tadros</dc:creator>
<dc:creator>Ahmad S Amin</dc:creator>
<dc:creator>Krystien V V Lieve</dc:creator>
<dc:creator>Pieter G Postema</dc:creator>
<dc:creator>Maarten Kooyman</dc:creator>
<dc:creator>Leander Beekman</dc:creator>
<dc:creator>Dujdao Sahasatas</dc:creator>
<dc:creator>Montawatt Amnueypol</dc:creator>
<dc:creator>Rungroj Krittayaphong</dc:creator>
<dc:creator>Somchai Prechawat</dc:creator>
<dc:creator>Alisara Anannab</dc:creator>
<dc:creator>Pattarapong Makarawate</dc:creator>
<dc:creator>Tachapong Ngarmukos</dc:creator>
<dc:creator>Keerapa Phusanti</dc:creator>
<dc:creator>Gumpanart Veerakul</dc:creator>
<dc:creator>Zoya Kingsbury</dc:creator>
<dc:creator>Taksina Newington</dc:creator>
<dc:creator>Uma Maheswari</dc:creator>
<dc:creator>Mark T Ross</dc:creator>
<dc:creator>Andrew Grace</dc:creator>
<dc:creator>Pier D Lambiase</dc:creator>
<dc:creator>Elijah R Behr</dc:creator>
<dc:creator>Jean-Jacques Schott</dc:creator>
<dc:creator>Richard Redon</dc:creator>
<dc:creator>Julien Barc</dc:creator>
<dc:creator>Vincent M Christoffels</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Koonlawee Nademanee</dc:creator>
<dc:creator>Connie R Bezzina</dc:creator>
<dc:creator>Apichai Khongphatthanayothin</dc:creator>
<dc:date>2024-10-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Rare Noncoding Enhancer Variant in &lt;em>;SCN5A&lt;/em>; Contributes to the High Prevalence of Brugada Syndrome in Thailand</dc:title>
<dc:identifier>pmid:39391988</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069041</dc:identifier>
</item>
<item>
<title>Using artificial intelligence to document the hidden RNA virosphere</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39389057/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>Current metagenomic tools can fail to identify highly divergent RNA viruses. We developed a deep learning algorithm, termed LucaProt, to discover highly divergent RNA-dependent RNA polymerase (RdRP) sequences in 10,487 metatranscriptomes generated from diverse global ecosystems. LucaProt integrates both sequence and predicted structural information, enabling the accurate detection of RdRP sequences. Using this approach, we identified 161,979 potential RNA virus species and 180 RNA virus...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 3:S0092-8674(24)01085-7. doi: 10.1016/j.cell.2024.09.027. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Current metagenomic tools can fail to identify highly divergent RNA viruses. We developed a deep learning algorithm, termed LucaProt, to discover highly divergent RNA-dependent RNA polymerase (RdRP) sequences in 10,487 metatranscriptomes generated from diverse global ecosystems. LucaProt integrates both sequence and predicted structural information, enabling the accurate detection of RdRP sequences. Using this approach, we identified 161,979 potential RNA virus species and 180 RNA virus supergroups, including many previously poorly studied groups, as well as RNA virus genomes of exceptional length (up to 47,250 nucleotides) and genomic complexity. A subset of these novel RNA viruses was confirmed by RT-PCR and RNA/DNA sequencing. Newly discovered RNA viruses were present in diverse environments, including air, hot springs, and hydrothermal vents, with virus diversity and abundance varying substantially among ecosystems. This study advances virus discovery, highlights the scale of the virosphere, and provides computational tools to better document the global RNA virome.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39389057/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39389057</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.027>10.1016/j.cell.2024.09.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39389057</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Xin Hou</dc:creator>
<dc:creator>Yong He</dc:creator>
<dc:creator>Pan Fang</dc:creator>
<dc:creator>Shi-Qiang Mei</dc:creator>
<dc:creator>Zan Xu</dc:creator>
<dc:creator>Wei-Chen Wu</dc:creator>
<dc:creator>Jun-Hua Tian</dc:creator>
<dc:creator>Shun Zhang</dc:creator>
<dc:creator>Zhen-Yu Zeng</dc:creator>
<dc:creator>Qin-Yu Gou</dc:creator>
<dc:creator>Gen-Yang Xin</dc:creator>
<dc:creator>Shi-Jia Le</dc:creator>
<dc:creator>Yin-Yue Xia</dc:creator>
<dc:creator>Yu-Lan Zhou</dc:creator>
<dc:creator>Feng-Ming Hui</dc:creator>
<dc:creator>Yuan-Fei Pan</dc:creator>
<dc:creator>John-Sebastian Eden</dc:creator>
<dc:creator>Zhao-Hui Yang</dc:creator>
<dc:creator>Chong Han</dc:creator>
<dc:creator>Yue-Long Shu</dc:creator>
<dc:creator>Deyin Guo</dc:creator>
<dc:creator>Jun Li</dc:creator>
<dc:creator>Edward C Holmes</dc:creator>
<dc:creator>Zhao-Rong Li</dc:creator>
<dc:creator>Mang Shi</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Using artificial intelligence to document the hidden RNA virosphere</dc:title>
<dc:identifier>pmid:39389057</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.027</dc:identifier>
</item>
<item>
<title>Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39389056/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 9:S0092-8674(24)01156-5. doi: 10.1016/j.cell.2024.10.008. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39389056/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39389056</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.008>10.1016/j.cell.2024.10.008</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39389056</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Abdeladim Moumen</dc:creator>
<dc:creator>Philip Masterson</dc:creator>
<dc:creator>Mark J O'Connor</dc:creator>
<dc:creator>Stephen P Jackson</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Retraction notice to: hnRNP K: An HDM2 Target and Transcriptional Coactivator of p53 in Response to DNA Damage</dc:title>
<dc:identifier>pmid:39389056</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.008</dc:identifier>
</item>
<item>
<title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39388581/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 10. doi: 10.1161/CIR.0000000000001294. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39388581/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39388581</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001294>10.1161/CIR.0000000000001294</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39388581</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Catherine M Otto</dc:creator>
<dc:creator>Mariell Jessup</dc:creator>
<dc:creator>Richard J Kovacs</dc:creator>
<dc:creator>Joshua A Beckman</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Optimizing AHA/ACC Guidelines for the Digital Age: Guidelines in Evolution</dc:title>
<dc:identifier>pmid:39388581</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001294</dc:identifier>
</item>
<item>
<title>Salt and CHIP: &lt;em>;Tet2&lt;/em>;-CH Aggravates Salt-Sensitive Hypertension in Mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39388535/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 11;135(9):951-953. doi: 10.1161/CIRCRESAHA.124.325364. Epub 2024 Oct 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39388535/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39388535</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325364>10.1161/CIRCRESAHA.124.325364</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39388535</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Caitlyn Vlasschaert</dc:creator>
<dc:creator>Steven D Crowley</dc:creator>
<dc:creator>Alexander G Bick</dc:creator>
<dc:date>2024-10-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Salt and CHIP: &lt;em>;Tet2&lt;/em>;-CH Aggravates Salt-Sensitive Hypertension in Mice</dc:title>
<dc:identifier>pmid:39388535</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325364</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39388534/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Oct 11;135(9):888-889. doi: 10.1161/RES.0000000000000696. Epub 2024 Oct 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39388534/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39388534</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000696>10.1161/RES.0000000000000696</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39388534</guid>
<pubDate>Thu, 10 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-10</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:39388534</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000696</dc:identifier>
</item>
<item>
<title>β-blockers after MI: does ABYSS confirm REDUCEd use after all?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384949/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Oct 9. doi: 10.1038/s41569-024-01093-z. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384949/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39384949</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01093-z>10.1038/s41569-024-01093-z</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384949</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Robin Hofmann</dc:creator>
<dc:creator>Stefan James</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>β-blockers after MI: does ABYSS confirm REDUCEd use after all?</dc:title>
<dc:identifier>pmid:39384949</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01093-z</dc:identifier>
</item>
<item>
<title>Tribute to an Outstanding Clinician and Friend Roman DeSanctis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384266/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1582-1583. doi: 10.1016/j.jacc.2024.08.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384266/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39384266</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.020>10.1016/j.jacc.2024.08.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384266</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Tribute to an Outstanding Clinician and Friend Roman DeSanctis</dc:title>
<dc:identifier>pmid:39384266</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.020</dc:identifier>
</item>
<item>
<title>Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384265/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1578-1581. doi: 10.1016/j.jacc.2024.07.036.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384265/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39384265</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.036>10.1016/j.jacc.2024.07.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384265</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Sungho Bea</dc:creator>
<dc:creator>Krista F Huybrechts</dc:creator>
<dc:creator>Heba H Edrees</dc:creator>
<dc:creator>C Andrew Basham</dc:creator>
<dc:creator>Seanna M Vine</dc:creator>
<dc:creator>Robert J Glynn</dc:creator>
<dc:creator>Brian T Bateman</dc:creator>
<dc:creator>Katsiaryna Bykov</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Opioid Overdose in Patients With Concomitant Use of Tramadol and Clopidogrel vs Alternative Antiplatelet Agents</dc:title>
<dc:identifier>pmid:39384265</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.036</dc:identifier>
</item>
<item>
<title>International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384264/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>Despite abundant clinical innovation and burgeoning scientific investigation, pulmonary embolism (PE) has continued to pose a diagnostic and management challenge worldwide. Aging populations, patients living with a mounting number of chronic medical conditions, particularly cancer, and increasingly prevalent health care disparities herald a growing burden of PE. In the meantime, navigating expanding strategies for immediate and long-term anticoagulation, as well as advanced therapies, including...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1561-1577. doi: 10.1016/j.jacc.2024.07.044.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite abundant clinical innovation and burgeoning scientific investigation, pulmonary embolism (PE) has continued to pose a diagnostic and management challenge worldwide. Aging populations, patients living with a mounting number of chronic medical conditions, particularly cancer, and increasingly prevalent health care disparities herald a growing burden of PE. In the meantime, navigating expanding strategies for immediate and long-term anticoagulation, as well as advanced therapies, including catheter-based interventions for patients with more severe PE, has become progressively daunting. Accordingly, clinicians frequently turn to evidence-based clinical practice guidelines for diagnostic and management recommendations. However, numerous international guidelines, heterogeneity in recommendations, as well as areas of uncertainty or omission may leave the readers and clinicians without a clear management pathway. In this review of international PE guidelines, we highlight key areas of consistency, difference, and lack of recommendations (silence) with an emphasis on critical clinical and research needs.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384264/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39384264</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.044>10.1016/j.jacc.2024.07.044</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384264</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Marco Zuin</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:creator>Jennifer Ballard-Hernandez</dc:creator>
<dc:creator>Stefano Barco</dc:creator>
<dc:creator>Elisabeth M Battinelli</dc:creator>
<dc:creator>George Giannakoulas</dc:creator>
<dc:creator>David Jimenez</dc:creator>
<dc:creator>Frederikus A Klok</dc:creator>
<dc:creator>Darsiya Krishnathasan</dc:creator>
<dc:creator>Irene M Lang</dc:creator>
<dc:creator>Lisa Moores</dc:creator>
<dc:creator>Katelyn W Sylvester</dc:creator>
<dc:creator>Jeffrey I Weitz</dc:creator>
<dc:creator>Gregory Piazza</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>International Clinical Practice Guideline Recommendations for Acute Pulmonary Embolism: Harmony, Dissonance, and Silence</dc:title>
<dc:identifier>pmid:39384264</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.044</dc:identifier>
</item>
<item>
<title>Optimizing Outcomes in ST-Segment Elevation Myocardial Infarction: Is Prolonged Infusion of Bivalirudin Part of the Solution?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1525-1527. doi: 10.1016/j.jacc.2024.08.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39384263</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.049>10.1016/j.jacc.2024.08.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384263</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Matthew A Cavender</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Optimizing Outcomes in ST-Segment Elevation Myocardial Infarction: Is Prolonged Infusion of Bivalirudin Part of the Solution?</dc:title>
<dc:identifier>pmid:39384263</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.049</dc:identifier>
</item>
<item>
<title>Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39384262/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Oct 15;84(16):1512-1524. doi: 10.1016/j.jacc.2024.07.045.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: In the BRIGHT-4 (Bivalirudin With Prolonged Full-Dose Infusion During Primary PCI Versus Heparin Trial-4), anticoagulation with bivalirudin plus a 2- to 4-hour high-dose infusion after percutaneous coronary intervention (PCI) reduced all-cause mortality and bleeding without increasing reinfarction or stent thrombosis compared with heparin alone in patients with ST-segment elevation myocardial infarction (STEMI). These findings require external validation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine outcomes of bivalirudin vs heparin anticoagulation during PCI in STEMI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We performed an individual-patient-data meta-analysis of all large randomized trials of bivalirudin vs heparin in STEMI patients undergoing primary PCI performed before BRIGHT-4. The primary endpoint was all-cause mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Six trials randomizing 15,254 patients were included. Pooled across all regimens of bivalirudin and glycoprotein IIb/IIIa inhibitor (GPI) use, bivalirudin reduced 30-day all-cause mortality (2.5% vs 2.9%; adjusted OR: 0.78; 95% CI: 0.62-0.99), cardiac mortality (adjusted OR: 0.69; 95% CI: 0.54-0.88), and major bleeding (adjusted OR: 0.53; 95% CI: 0.44-0.64) but increased reinfarction (adjusted OR: 1.30; 95% CI: 1.02-1.65) and stent thrombosis (adjusted OR: 1.43; 95% CI: 1.05-1.93) compared with heparin. In 4 trials in which 6,244 patients were randomized to bivalirudin plus a high-dose post-PCI infusion vs heparin without planned GPI use (the BRIGHT-4 regimens), 30-day all-cause mortality occurred in 1.8% vs 2.9% of patients, respectively (adjusted OR: 0.74; 95% CI: 0.48-1.12), and bivalirudin reduced cardiac mortality (adjusted OR: 0.62; 95% CI: 0.39-0.97) and major bleeding (adjusted OR: 0.49; 95% CI: 0.35-0.70), with similar rates of reinfarction (adjusted OR: 0.89; 95% CI: 0.58-1.38) and stent thrombosis (adjusted OR: 0.80; 95% CI: 0.41-1.57).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In STEMI patients undergoing primary PCI, bivalirudin with a 2- to 4-hour post-PCI high-dose infusion reduced cardiac mortality and major bleeding without an increase in ischemic events compared with heparin monotherapy with provisional GPI use, confirming the BRIGHT-4 results.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39384262/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39384262</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.07.045>10.1016/j.jacc.2024.07.045</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39384262</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>David Erlinge</dc:creator>
<dc:creator>Yaling Han</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Rod H Stables</dc:creator>
<dc:creator>Enrico Frigoli</dc:creator>
<dc:creator>Stefan K James</dc:creator>
<dc:creator>Yi Li</dc:creator>
<dc:creator>Patrick Goldstein</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Ghazaleh Mehdipoor</dc:creator>
<dc:creator>Aaron Crowley</dc:creator>
<dc:creator>Shmuel Chen</dc:creator>
<dc:creator>Björn Redfors</dc:creator>
<dc:creator>Clayton Snyder</dc:creator>
<dc:creator>Zhipeng Zhou</dc:creator>
<dc:creator>Behnood Bikdeli</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results</dc:title>
<dc:identifier>pmid:39384262</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.07.045</dc:identifier>
</item>
<item>
<title>Structure of TnsABCD transpososome reveals mechanisms of targeted DNA transposition</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39383864/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>Tn7-like transposons are characterized by their ability to insert specifically into host chromosomes. Recognition of the attachment (att) site by TnsD recruits the TnsABC proteins to form the transpososome and facilitate transposition. Although this pathway is well established, atomic-level structural insights of this process remain largely elusive. Here, we present the cryo-electron microscopy (cryo-EM) structures of the TnsC-TnsD-att DNA complex and the TnsABCD transpososome from the Tn7-like...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 8:S0092-8674(24)01071-7. doi: 10.1016/j.cell.2024.09.023. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tn7-like transposons are characterized by their ability to insert specifically into host chromosomes. Recognition of the attachment (att) site by TnsD recruits the TnsABC proteins to form the transpososome and facilitate transposition. Although this pathway is well established, atomic-level structural insights of this process remain largely elusive. Here, we present the cryo-electron microscopy (cryo-EM) structures of the TnsC-TnsD-att DNA complex and the TnsABCD transpososome from the Tn7-like transposon in Peltigera membranacea cyanobiont 210A, a type I-B CRISPR-associated transposon. Our structures reveal a striking bending of the att DNA, featured by the intercalation of an arginine side chain of TnsD into a CC/GG dinucleotide step. The TnsABCD transpososome structure reveals TnsA-TnsB interactions and demonstrates that TnsC not only recruits TnsAB but also directly participates in the transpososome assembly. These findings provide mechanistic insights into targeted DNA insertion by Tn7-like transposons, with implications for improving the precision and efficiency of their genome-editing applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39383864/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39383864</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.023>10.1016/j.cell.2024.09.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39383864</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Shukun Wang</dc:creator>
<dc:creator>Romana Siddique</dc:creator>
<dc:creator>Mark C Hall</dc:creator>
<dc:creator>Phoebe A Rice</dc:creator>
<dc:creator>Leifu Chang</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Structure of TnsABCD transpososome reveals mechanisms of targeted DNA transposition</dc:title>
<dc:identifier>pmid:39383864</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.023</dc:identifier>
</item>
<item>
<title>A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39383863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 4:S0092-8674(24)01084-5. doi: 10.1016/j.cell.2024.09.026. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) evolution has resulted in viral escape from clinically authorized monoclonal antibodies (mAbs), creating a need for mAbs that are resilient to epitope diversification. Broadly neutralizing coronavirus mAbs that are sufficiently potent for clinical development and retain activity despite viral evolution remain elusive. We identified a human mAb, designated VIR-7229, which targets the viral receptor-binding motif (RBM) with unprecedented cross-reactivity to all sarbecovirus clades, including non-ACE2-utilizing bat sarbecoviruses, while potently neutralizing SARS-CoV-2 variants since 2019, including the recent EG.5, BA.2.86, and JN.1. VIR-7229 tolerates extraordinary epitope variability, partly attributed to its high binding affinity, receptor molecular mimicry, and interactions with RBM backbone atoms. Consequently, VIR-7229 features a high barrier for selection of escape mutants, which are rare and associated with reduced viral fitness, underscoring its potential to be resilient to future viral evolution. VIR-7229 is a strong candidate to become a next-generation medicine.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39383863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39383863</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.026>10.1016/j.cell.2024.09.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39383863</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Laura E Rosen</dc:creator>
<dc:creator>M Alejandra Tortorici</dc:creator>
<dc:creator>Anna De Marco</dc:creator>
<dc:creator>Dora Pinto</dc:creator>
<dc:creator>William B Foreman</dc:creator>
<dc:creator>Ashley L Taylor</dc:creator>
<dc:creator>Young-Jun Park</dc:creator>
<dc:creator>Dana Bohan</dc:creator>
<dc:creator>Tyson Rietz</dc:creator>
<dc:creator>John M Errico</dc:creator>
<dc:creator>Kevin Hauser</dc:creator>
<dc:creator>Ha V Dang</dc:creator>
<dc:creator>Justin W Chartron</dc:creator>
<dc:creator>Martina Giurdanella</dc:creator>
<dc:creator>Giuseppe Cusumano</dc:creator>
<dc:creator>Christian Saliba</dc:creator>
<dc:creator>Fabrizia Zatta</dc:creator>
<dc:creator>Kaitlin R Sprouse</dc:creator>
<dc:creator>Amin Addetia</dc:creator>
<dc:creator>Samantha K Zepeda</dc:creator>
<dc:creator>Jack Brown</dc:creator>
<dc:creator>Jimin Lee</dc:creator>
<dc:creator>Exequiel Dellota</dc:creator>
<dc:creator>Anushka Rajesh</dc:creator>
<dc:creator>Julia Noack</dc:creator>
<dc:creator>Qiqing Tao</dc:creator>
<dc:creator>Yvonne DaCosta</dc:creator>
<dc:creator>Brian Tsu</dc:creator>
<dc:creator>Rima Acosta</dc:creator>
<dc:creator>Sambhavi Subramanian</dc:creator>
<dc:creator>Guilherme Dias de Melo</dc:creator>
<dc:creator>Lauriane Kergoat</dc:creator>
<dc:creator>Ivy Zhang</dc:creator>
<dc:creator>Zhuoming Liu</dc:creator>
<dc:creator>Barbara Guarino</dc:creator>
<dc:creator>Michael A Schmid</dc:creator>
<dc:creator>Gretja Schnell</dc:creator>
<dc:creator>Jessica L Miller</dc:creator>
<dc:creator>Florian A Lempp</dc:creator>
<dc:creator>Nadine Czudnochowski</dc:creator>
<dc:creator>Elisabetta Cameroni</dc:creator>
<dc:creator>Sean P J Whelan</dc:creator>
<dc:creator>Hervé Bourhy</dc:creator>
<dc:creator>Lisa A Purcell</dc:creator>
<dc:creator>Fabio Benigni</dc:creator>
<dc:creator>Julia di Iulio</dc:creator>
<dc:creator>Matteo Samuele Pizzuto</dc:creator>
<dc:creator>Antonio Lanzavecchia</dc:creator>
<dc:creator>Amalio Telenti</dc:creator>
<dc:creator>Gyorgy Snell</dc:creator>
<dc:creator>Davide Corti</dc:creator>
<dc:creator>David Veesler</dc:creator>
<dc:creator>Tyler N Starr</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification</dc:title>
<dc:identifier>pmid:39383863</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.026</dc:identifier>
</item>
<item>
<title>Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39383862/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>Aberrant expression of repeat RNAs in pancreatic ductal adenocarcinoma (PDAC) mimics viral-like responses with implications on tumor cell state and the response of the surrounding microenvironment. To better understand the relationship of repeat RNAs in human PDAC, we performed spatial molecular imaging at single-cell resolution in 46 primary tumors, revealing correlations of high repeat RNA expression with alterations in epithelial state in PDAC cells and myofibroblast phenotype in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Oct 1:S0092-8674(24)01072-9. doi: 10.1016/j.cell.2024.09.024. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Aberrant expression of repeat RNAs in pancreatic ductal adenocarcinoma (PDAC) mimics viral-like responses with implications on tumor cell state and the response of the surrounding microenvironment. To better understand the relationship of repeat RNAs in human PDAC, we performed spatial molecular imaging at single-cell resolution in 46 primary tumors, revealing correlations of high repeat RNA expression with alterations in epithelial state in PDAC cells and myofibroblast phenotype in cancer-associated fibroblasts (CAFs). This loss of cellular identity is observed with dosing of extracellular vesicles (EVs) and individual repeat RNAs of PDAC and CAF cell culture models pointing to cell-cell intercommunication of these viral-like elements. Differences in PDAC and CAF responses are driven by distinct innate immune signaling through interferon regulatory factor 3 (IRF3). The cell-context-specific viral-like responses to repeat RNAs provide a mechanism for modulation of cellular plasticity in diverse cell types in the PDAC microenvironment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39383862/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39383862</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.09.024>10.1016/j.cell.2024.09.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39383862</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Eunae You</dc:creator>
<dc:creator>Patrick Danaher</dc:creator>
<dc:creator>Chenyue Lu</dc:creator>
<dc:creator>Siyu Sun</dc:creator>
<dc:creator>Luli Zou</dc:creator>
<dc:creator>Ildiko E Phillips</dc:creator>
<dc:creator>Alexandra S Rojas</dc:creator>
<dc:creator>Natalie I Ho</dc:creator>
<dc:creator>Yuhui Song</dc:creator>
<dc:creator>Michael J Raabe</dc:creator>
<dc:creator>Katherine H Xu</dc:creator>
<dc:creator>Peter M Richieri</dc:creator>
<dc:creator>Hao Li</dc:creator>
<dc:creator>Natalie Aston</dc:creator>
<dc:creator>Rebecca L Porter</dc:creator>
<dc:creator>Bidish K Patel</dc:creator>
<dc:creator>Linda T Nieman</dc:creator>
<dc:creator>Nathan Schurman</dc:creator>
<dc:creator>Briana M Hudson</dc:creator>
<dc:creator>Khrystyna North</dc:creator>
<dc:creator>Sarah E Church</dc:creator>
<dc:creator>Vikram Deshpande</dc:creator>
<dc:creator>Andrew S Liss</dc:creator>
<dc:creator>Tae K Kim</dc:creator>
<dc:creator>Yi Cui</dc:creator>
<dc:creator>Youngmi Kim</dc:creator>
<dc:creator>Benjamin D Greenbaum</dc:creator>
<dc:creator>Martin J Aryee</dc:creator>
<dc:creator>David T Ting</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer</dc:title>
<dc:identifier>pmid:39383862</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.09.024</dc:identifier>
</item>
<item>
<title>Error in Figure 1</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382877/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3703. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382877/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39382877</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3703>10.1001/jamacardio.2024.3703</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382877</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Error in Figure 1</dc:title>
<dc:identifier>pmid:39382877</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3703</dc:identifier>
</item>
<item>
<title>Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382876/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION AND RELEVANCE: Results of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT. However, an increased risk of MACCE cannot be excluded, and 3 months of DAPT followed by potent P2Y12 inhibitor monotherapy was ranked as the best option to reduce MACCE. Because...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3216. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To analyze the efficacy and safety of DAPT strategies in patients with ACS using a bayesian network meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: MEDLINE, Embase, Cochrane, and LILACS databases were searched from inception to April 8, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Randomized clinical trials (RCTs) comparing DAPT duration strategies in patients with ACS undergoing PCI were selected. Short-term strategies (1 month of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by P2Y12 inhibitors, 3 months of DAPT followed by aspirin, and 6 months of DAPT followed by aspirin) were compared with conventional 12 months of DAPT.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: This systematic review and network meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. The risk ratio (RR) with a 95% credible interval (CrI) was calculated within a bayesian random-effects network meta-analysis. Treatments were ranked using surface under the cumulative ranking (SUCRA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary efficacy end point was major adverse cardiac and cerebrovascular events (MACCE); the primary safety end point was major bleeding.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 15 RCTs randomizing 35 326 patients (mean [SD] age, 63.1 [11.1] years; 26 954 male [76.3%]; 11 339 STEMI [32.1%]) with ACS were included. A total of 24 797 patients (70.2%) received potent P2Y12 inhibitors (ticagrelor or prasugrel). Compared with 12 months of DAPT, 1 month of DAPT followed by P2Y12 inhibitors reduced major bleeding (RR, 0.47; 95% CrI, 0.26-0.74) with no difference in MACCE (RR, 1.00; 95% CrI, 0.70-1.41). No significant differences were observed in MACCE incidence between strategies, although CrIs were wide. SUCRA ranked 1 month of DAPT followed by P2Y12 inhibitors as the best for reducing major bleeding and 3 months of DAPT followed by P2Y12 inhibitors as optimal for reducing MACCE (RR, 0.85; 95% CrI, 0.56-1.21).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION AND RELEVANCE: Results of this systematic review and network meta-analysis reveal that, in patients with ACS undergoing PCI with DES, 1 month of DAPT followed by potent P2Y12 inhibitor monotherapy was associated with a reduction in major bleeding without increasing MACCE when compared with 12 months of DAPT. However, an increased risk of MACCE cannot be excluded, and 3 months of DAPT followed by potent P2Y12 inhibitor monotherapy was ranked as the best option to reduce MACCE. Because most patients receiving P2Y12 inhibitor monotherapy were taking ticagrelor, the safety of stopping aspirin in those taking clopidogrel remains unclear.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382876/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39382876</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3216>10.1001/jamacardio.2024.3216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382876</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Pedro E P Carvalho</dc:creator>
<dc:creator>Douglas M Gewehr</dc:creator>
<dc:creator>Bruno R Nascimento</dc:creator>
<dc:creator>Lara Melo</dc:creator>
<dc:creator>Giullia Burkhardt</dc:creator>
<dc:creator>André Rivera</dc:creator>
<dc:creator>Marcelo A P Braga</dc:creator>
<dc:creator>Patricia O Guimarães</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>Marco Valgimigli</dc:creator>
<dc:creator>Dominick J Angiolillo</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Yader Sandoval</dc:creator>
<dc:creator>Shao-Liang Chen</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes: A Systematic Review and Network Meta-Analysis</dc:title>
<dc:identifier>pmid:39382876</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3216</dc:identifier>
</item>
<item>
<title>Ventricular Septal Rupture After ST-Segment Elevation Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382857/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3308. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382857/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39382857</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3308>10.1001/jamacardio.2024.3308</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382857</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Alex Melot</dc:creator>
<dc:creator>Pierre Groussin</dc:creator>
<dc:creator>Raphaël P Martins</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Ventricular Septal Rupture After ST-Segment Elevation Myocardial Infarction</dc:title>
<dc:identifier>pmid:39382857</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3308</dc:identifier>
</item>
<item>
<title>Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39382856/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241011121246&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Oct 9. doi: 10.1001/jamacardio.2024.3241. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Historically, women with aortic stenosis have experienced worse outcomes and inadequate recognition compared to men, being both underdiagnosed and undertreated, while also facing underrepresentation in clinical trials.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine whether women with small aortic annuli undergoing transcatheter aortic valve replacement have better clinical and hemodynamic outcomes with a self-expanding valve (SEV) or balloon-expandable valve (BEV).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, PARTICIPANTS: The Small Annuli Randomized to Evolut or SAPIEN Trial (SMART) was a large-scale randomized clinical trial focusing on patients with small aortic annuli undergoing transcatheter aortic valve replacement, randomized to receive SEVs or BEVs and included 716 patients treated at 83 centers in Canada, Europe, Israel, and the US from April 2021 to October 2022. This prespecified secondary analysis reports clinical and hemodynamic findings for all 621 women enrolled in SMART. Data for this report were analyzed from February to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Transcatheter aortic valve replacement with an SEV or a BEV.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The composite coprimary clinical end point comprised death, disabling stroke, or heart failure-related rehospitalization. The coprimary valve function end point was the incidence of bioprosthetic valve dysfunction, both assessed through 12 months. Secondary end points included the incidence of moderate or severe prosthesis-patient mismatch.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 621 women (mean [SD] age, 80.2 [6.2] years; 312 randomized to the SEV group and 309 to the BEV group) were included in the present analysis. At 12 months, there were no significant differences in the coprimary clinical end point between the SEV and BEV groups (9.4% vs 11.8%, absolute risk difference -2.3%; 95% CI -7.2 to 2.5, P = .35). However, SEV implantation was associated with less bioprosthetic valve dysfunction (8.4% vs 41.8%; absolute risk difference, -33.4%; 95% CI, -40.4 to -26.4; P &lt; .001). SEV implantation resulted in lower aortic valve gradients and larger effective orifice areas at 30 days and 12 months and less mild or greater aortic regurgitation at 12 months compared to BEV implantation. Prosthesis-patient mismatch was significantly lower with SEVs, regardless of the definition used and adjustment for body mass index. Use of SEVs was associated with better quality of life outcomes as assessed by the Valve Academic Research Consortium-3 ordinal quality of life measure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among women with severe symptomatic aortic stenosis and small aortic annuli undergoing transcatheter aortic valve replacement, the use of SEVs, compared to BEVs, resulted in similar clinical outcomes and a markedly reduced incidence of bioprosthetic valve dysfunction through 12 months, including a lower risk of prosthesis-patient mismatch and better 12-month quality of life.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04722250.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39382856/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241011121246&v=2.18.0.post9+e462414">39382856</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.3241>10.1001/jamacardio.2024.3241</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39382856</guid>
<pubDate>Wed, 09 Oct 2024 06:00:00 -0400</pubDate>
<dc:creator>Didier Tchétché</dc:creator>
<dc:creator>Roxana Mehran</dc:creator>
<dc:creator>Daniel J Blackman</dc:creator>
<dc:creator>Ramzi F Khalil</dc:creator>
<dc:creator>Helge Möllmann</dc:creator>
<dc:creator>Mohamed Abdel-Wahab</dc:creator>
<dc:creator>Walid Ben Ali</dc:creator>
<dc:creator>Paul D Mahoney</dc:creator>
<dc:creator>Hendrik Ruge</dc:creator>
<dc:creator>Sabine Bleiziffer</dc:creator>
<dc:creator>Lang Lin</dc:creator>
<dc:creator>Molly Szerlip</dc:creator>
<dc:creator>Kendra J Grubb</dc:creator>
<dc:creator>Isida Byku</dc:creator>
<dc:creator>Mayra Guerrero</dc:creator>
<dc:creator>Linda D Gillam</dc:creator>
<dc:creator>Anna Sonia Petronio</dc:creator>
<dc:creator>Guilherme F Attizzani</dc:creator>
<dc:creator>Wayne B Batchelor</dc:creator>
<dc:creator>Hemal Gada</dc:creator>
<dc:creator>Toby Rogers</dc:creator>
<dc:creator>Joshua D Rovin</dc:creator>
<dc:creator>Brian Whisenant</dc:creator>
<dc:creator>Stewart Benton</dc:creator>
<dc:creator>Blake Gardner</dc:creator>
<dc:creator>Ratnasari Padang</dc:creator>
<dc:creator>Andrew D Althouse</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:date>2024-10-09</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39382856</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.3241</dc:identifier>
</item>





























</channel>
</rss>